504-30-3Relevant academic research and scientific papers
Infrared matrix isolation and ab initio studies of 3(2H)-pyridazinone and photoproduced 3-hydroxypyridazine
Lapinski, Leszek,Fulara, Jan,Czerminski, Ryszard,Nowak, Maciej J.
, p. 1087 - 1096 (1990)
The infrared spectra of 3(2H)-pyridazinone and its rare tautomeric form, 3-hydroxypyridazine, isolated in an argon matrix are reported and discussed.Only the first tautomer was observed after deposition of the matrix.The second form was photochemically pr
Oxidative addition of haloheteroarenes to palladium(0): Concerted versus SNAr-type mechanism
Maes, Bert U. W.,Verbeeck, Stefan,Verhelst, Tom,Ekomié, Audrey,Von Wolff, Niklas,Lefèvre, Guillaume,Mitchell, Emily A.,Jutand, Anny
, p. 7858 - 7865 (2015)
The kinetics of the oxidative additions of haloheteroarenes HetX (X=I, Br, Cl) to [Pd0(PPh3)2] (generated from [Pd0(PPh3)4]) have been investigated in THF and DMF and the rate constants have been determined. In contrast to the generally accepted concerted mechanism, Hammett plots obtained for substituted 2-halopyridines and solvent effects reveal a reaction mechanism dependent on the halide X of HetX: an unprecedented SNAr-type mechanism for X=Br or Cl and a classical concerted mechanism for X=I. These results are supported by DFT studies.
Synthetic method of pyridazinone
-
Paragraph 0022-0031, (2021/03/30)
The invention relates to a new process for synthesizing pyridazinone, which is characterized in that C-TiO2 solid acid with a core-shell structure is used as a catalyst to replace traditional glacialacetic acid, tetramethyl ammonium bromide serves as a phase transfer catalyst, tert-butylhydrazine and furochloric acid are adopted to synthesize pyridazinone under certain conditions, the reaction efficiency is improved by adding the catalyst, and alkali washing and water washing processes are omitted, so that the yield and the quality of the product are improved, and the generation of three wastes is greatly reduced.
PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON
-
Page/Page column, (2014/07/07)
The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.
Ring-closing metathesis for the synthesis of heteroaromatics: evaluating routes to pyridines and pyridazines
Donohoe, Timothy J.,Bower, John F.,Basutto, José A.,Fishlock, Lisa P.,Procopiou, Panayiotis A.,Callens, Cedric K.A.
experimental part, p. 8969 - 8980 (2009/12/26)
Ring-closing olefin metathesis (RCM) has been applied to the efficient synthesis of densely and diversely substituted pyridine and pyridazine frameworks. Routes to suitable metathesis precursors have been investigated and the scope of the metathesis step has been probed. The metathesis products function as precursors to the target heteroaromatic structures via elimination of a suitable leaving group, which also facilitates earlier steps by serving as a protecting group at nitrogen. Further functionalisation of the metathesis products is possible both prior to and after aromatisation. The net result is a powerful strategy for the de novo synthesis of highly substituted heteroaromatic scaffolds.
Synthesis of substituted pyridines and pyridazines via ring closing metathesis
Donohoe, Timothy J.,Fishlock, Lisa P.,Basutto, Jose A.,Bower, John F.,Procopiou, Panayiotis A.,Thompson, Amber L.
supporting information; experimental part, p. 3008 - 3010 (2009/12/01)
RCM can be used to make aromatic heterocycles, namely pyridines and, for the first time, pyridazines; the key step after RCM involves elimination of sulfinate to provide the aromatic system. The Royal Society of Chemistry 2009.
N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy
Tavares, Francis X.,Boucheron, Joyce A.,Dickerson, Scott H.,Griffin, Robert J.,Preugschat, Frank,Thomso, Stephen A.,Wang, Tony Y.,Zhouf, Hui-Qiang
, p. 4716 - 4730 (2007/10/03)
Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.
Endothelin receptor antagonists
-
, (2008/06/13)
This invention relates to pyridizinone derivatives of formula I STR1 wherein the various substituents are defined in the specification, and salts thereof, which have useful pharmacological properties, in particular endothelin receptor-antagonistic properties. The compounds are thus useful for the treatment of illnesses associated with endothelin activities, such as hypertension, cardiac insufficiency, coronary heart disease, renal, cerebral and myocardial ischaemia, renal insufficiency, cerebral infarct, subarachnoid haemorrhage, arteriosclerosis pulmonary high blood pressure, inflammations, asthma, prostate hyperplasia, endotoxic shock and in complications after the administration of immunosuppressants which produce renal vasoconstriction.
Cycloaddition of benzonitrile oxide to pyridazine, pyrimidine and pyrazine
Corsaro, Antonino,Perrini, Giancarlo,Pistara, Venerando,Quadrelli, Paolo,Gamba Invernizzi, Anna,Caramella, Pierluigi
, p. 6421 - 6436 (2007/10/03)
Cycloaddition of benzonitrile oxide to pyridazine affords an isolable mono-cycloadduct. In cycloadditions to pyrimidine and pyrazine the primary mono-cycloadducts are labile intermediates which undergo further cycloaddition affording isolable bis- and tris-cycloadducts.
Reaction of Diazines and their Benzo derivatives with Benzonitrile oxide
Grassi, Giovanni,Risitano, Francesco,Foti, Francesco
, p. 11855 - 11862 (2007/10/02)
The reaction of diazines 1 and benzodiazines 2 with benzonitrile oxide in refluxing benzene affords regio, site and stereospecific cycloadducts to the diazine ring and/i43or products derived from them.
